Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global High Potency Active Pharmaceutical Ingredient (HPAPI) market finds that the global High Potency Active Pharmaceutical Ingredient (HPAPI) market reached a value of USD 30461.01 million in 2022. It’s expected that the market will achieve USD 48168.68 million by 2028, exhibiting a CAGR of 7.94% during the forecast period.

Opportunities

Many large pharmaceutical manufacturers have installed internal HPAPI manufacturing capabilities, but most small and medium-sized companies do not have the resources to do so. Some larger pharmaceutical companies invest only in commercial-scale production systems and rely on contract service providers in the early stages of development. In addition, some companies with HPAPI capabilities are closing or divesting their facilities for outsourcing.
Although internal HPAPI manufacturing currently occupies a large market share, HPAPI manufacturing outsourcing is growing rapidly. Outsourcing allows large drug manufacturers to focus on drug discovery and product launches, lifecycle management and other activities. In addition, it can save costs. Outsourcing is also often a strategy for mitigating risk. For smaller companies, they can use contract manufacturing services to access the expertise needed for HPAPI production.
Contract manufacturing and outsourcing of HPAPI molecular development in the pharmaceutical industry is a growing trend. With the advancement of production technology, such as the introduction of one-time production and batch culture fermentation technology for separating molecules, it is expected to provide opportunities for contract manufacturing in the next few years.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

The top three companies are Teva Pharmaceutical Industries, Pfizer and Merck KGaA with the revenue market share of 3.89%, 2.68% and 1.12% in 2019.

Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. Teva is committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one of the largest and most complex supply chains in the pharmaceutical industry.

Pfizer is a leading research-based biopharmaceutical company. Pfizer applies science and its global resources to deliver innovative therapies that extend and significantly improve lives. Pfizer makes medicines and vaccines that help people when they are sick and prevent them from getting sick in the first place, as well as some of the world’s best-known consumer healthcare brands.

Segmentation Overview:

Among different product types, Branded HPAPI segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Oncology Drugs segment occupied the biggest share from 2018 to 2022.

Key Companies in the global High Potency Active Pharmaceutical Ingredient (HPAPI) market covered in Chapter 3:

Dishman group
Cambrex Corporation
Teva Pharmaceutical Industries
Merck KGaA
Lonza Group
Patheon N.V.
Sun Pharmaceutical
Novasep
Dr. Reddy’s Laboratories
Alkermes PLC
Glenmark
Pfizer

In Chapter 4 and Chapter 14.2, on the basis of types, the High Potency Active Pharmaceutical Ingredient (HPAPI) market from 2018 to 2029 is primarily split into:

Branded HPAPI
Generic HPAPI

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the High Potency Active Pharmaceutical Ingredient (HPAPI) market from 2018 to 2029 covers:

Oncology Drugs
Anti-diabetic Drugs
Cardiovascular Drugs
Central Nervous System Drugs
Musculoskeletal Drugs

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)